Is it feasible to treat polycystic ovarian syndrome with or without insulin resistance using glucokinase activators as novel hypoglycaemic medications? A protocol for a systematic review and meta-analysis
Introduction A variety of hypoglycaemic drugs are used to treat polycystic ovarian syndrome (PCOS), but their efficacy remains insufficient. Glucokinase activators (GKAs) are a unique class of hypoglycaemic medications with emerging potential, notably in significantly reducing insulin resistance (IR...
Saved in:
| Main Authors: | Xiaojing Liu, Lei Zeng, Shuo Yuan, Genping Zeng, Xijing Lu, Peiyin Li, Tan Zeng, Zitong Lin, Yuxi Miao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/12/e088484.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glycaemic control and prevalence of hypoglycaemic events in children and adolescents with type 1 diabetes mellitus treated with insulin analogues
by: Plavšić Ljiljana, et al.
Published: (2014-01-01) -
Assessment of serum insulin in polycystic ovarian syndrome
by: Asia Rasul Bayez Hamkol, et al.
Published: (2025-04-01) -
Gut microbiota: an emerging target connecting polycystic ovarian syndrome and insulin resistance
by: Yufeng Mei, et al.
Published: (2025-03-01) -
Determination of insulin resistance, adiponectin and leptin in overweight women with polycystic ovarian syndrome
by: Sara Sardar Hamad, et al.
Published: (2025-08-01) -
Perioperative management of novel oral hypoglycaemic agents
by: Faida Al-Maiyah, et al.
Published: (2025-09-01)